Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Open this folder and view contents7. The editorial process
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Close this folder13. Partnership and collaboration
View the document13.1 The importance of supportive partners
View the document13.2 Possibilities at national, regional and international levels
Open this folder and view contents13.3 Various forms of collaboration
View the document13.4 Identifying partners and networks
View the document13.5 Clearly define conditions for partnership
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information

13.4 Identifying partners and networks

A remarkable number of organizations and individuals are actively working on health issues. To identify a potential partner, it is important to understand its objectives and to recognise the driving forces of the organization. Unfortunately, many patients’ organizations and associations of health professionals are sponsored by pharmaceutical companies and are therefore to an uncomfortable extent tied to the industry’s goals. This is liable to cause conflicts of interest and can create pressure on the bulletin to tone down its conclusions and avoid publishing critical articles; fears about how sponsors might react can make potential partners hesitate to help a drug bulletin.

When seeking partners, it is worth asking the advice of organizations that have already proved their commitment to the promotion of rational drug use. Box 13.3 lists some international organizations that promote the rational use of drugs. Box 13.4 is a list of questions you may want to ask potential partners and networks.

Box 13.3 Some organizations promoting the rational use of drugs

• International Society of Drug Bulletins (ISDB) []

• Healthy Skepticism []

• Health Action International (HAI) []

• The International Network for Rational Use of Drugs (INRUD) []

• E-Drug: []

• Cochrane Collaboration []

• Scottish Intercollegiate Guidelines Network (SIGN) []

• WHO:Department of Medicines Policy and Standards Policy, WHO Geneva

• No free lunch []

Box 13.4 Questions to ask of potential partners and networks

• Who are the founders and/or members of the organization?

• What are its main objectives?

• If this is a network, who are the partner organizations?

• Who does the network represent?

• From what sources does the organization get funding?

• What have been the organization’s recent activities? Does it have some recent examples of its work, such as publications or other written materials?

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014